Explore our range of useful resources below, designed to support you with your decision making. You can download the files to refer to later.
▼Beovu® (brolucizumab) is indicated in adults for the treatment of neovascular (wet) AMD and visual impairment due to diabetic macular oedema (DMO).1,2
Formulary application pack for Beovu® in wAMD
Information intended to support you with your local formulary submission for Beovu; for the treatment of patients with wet age-related macular degeneration (wAMD).
Registration is required to access this resource.
Formulary application pack for Beovu® in DMO
Information intended to support you with your local formulary submission for Beovu; for the treatment of patients with visual impairment due to diabetic macular oedema (DMO).
Registration is required to access this resource.
Request for budget impact model call
Request a conversation with a Novartis Account Manager to discuss the Beovu budget impact model, which supports an assessment of the impact of Beovu on service capacity and costs.
Request value proposition call
Request a conversation with a Novartis Account Manager to view the Beovu value proposition, which provides an overview of the clinical, system and service benefits.
If you are also a UK healthcare professional you can click below to view more information on ▼Beovu® (brolucizumab).
This link will take you to promotional information about Novartis products, therapy area materials and professional resources.
AMD, age-related macular degeneration; DMO, diabetic macular oedema; NHS, National Health Service; NICE, National Institute for Health and Care Excellence; SMC, Scottish Medicines Consortium; wAMD, wet AMD.
Reference
- Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics, Great Britain, April 2022.
- Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics, Northern Ireland, March 2022.
- National Institute for Health and Care Excellence (2021) Brolucizumab for treating wet age-related macular degeneration (NICE guideline 672). Available at: https://www.nice.org.uk/guidance/ta672. [Accessed May 2022].
- Scottish Medicines Consortium. Available at: https://www.scottishmedicines.org.uk/medicines-advice/brolucizumab-beovu-full-smc2272/ [Accessed May 2022].
